SNDX Syndax Pharmaceuticals, Inc.
High-Growth Software
F 30.0 / 100 pillar composite

AlphaQuality composite grade, weighted for high-growth software businesses.

⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.

Grade overrides the 30.0 pillar composite — hard gates always win.

Profitability

Weight: 15%
F 0
  • 5yr Avg ROIC -27.4%
  • Operating Margin Trend -88.61 pp/yr

Capital Efficiency

Weight: 15%
F 0
  • 5yr Avg ROE -123.2%
  • 5yr Share-Count CAGR 16.0%

Growth Quality

Weight: 35%
A- 82
  • 5yr Revenue CAGR 157.7%
  • Revenue-Growth Years (5) 2/5

Cash Generation

Weight: 20%
D+ 44
  • 5yr FCF Margin -442.6%
  • 5yr FCF/NI Conversion 1.16x

Balance Sheet

Weight: 10%
F 0
  • Net Debt / EBITDA 10.00x
  • Interest Coverage (EBIT/Int) -7.45x
  • Altman Z-Score -2.71

Stability

Weight: 5%
C 52
  • Negative-Revenue Years (5) 0/5
  • Piotroski F-Score 1

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Dumping

1 of 2 gurus held; 1 trimmed; 2 full exits.

Holders
1 -1
Avg Δ position
-22.6%
New buys
0
Full exits
2
As of Q2 2026